Literature DB >> 31204686

Structures of soluble rabbit neprilysin complexed with phosphoramidon or thiorphan.

Shaunivan L Labiuk1, Jurgen Sygusch2, Pawel Grochulski1.   

Abstract

Neutral endopeptidase (neprilysin; NEP) is a proteinase that cleaves a wide variety of peptides and has been implicated in Alzheimer's disease, cardiovascular conditions, arthritis and other inflammatory diseases. The structure of the soluble extracellular domain (residues 55-750) of rabbit neprilysin was solved both in its native form at 2.1 Å resolution, and bound to the inhibitors phosphoramidon and thiorphan at 2.8 and 3.0 Å resolution, respectively. Consistent with the extracellular domain of human neprilysin, the structure reveals a large central cavity which contains the active site and the location for inhibitor binding.

Entities:  

Keywords:  neprilysin; neutral endopeptidase; phosphoramidon; thiorphan

Mesh:

Substances:

Year:  2019        PMID: 31204686      PMCID: PMC6572095          DOI: 10.1107/S2053230X19006046

Source DB:  PubMed          Journal:  Acta Crystallogr F Struct Biol Commun        ISSN: 2053-230X            Impact factor:   1.056


  32 in total

1.  SuperPose: a simple server for sophisticated structural superposition.

Authors:  Rajarshi Maiti; Gary H Van Domselaar; Haiyan Zhang; David S Wishart
Journal:  Nucleic Acids Res       Date:  2004-07-01       Impact factor: 16.971

2.  Secretion of a functional soluble form of neutral endopeptidase-24.11 from a baculovirus-infected insect cell line.

Authors:  F Fossiez; G Lemay; N Labonté; F Parmentier-Lesage; G Boileau; P Crine
Journal:  Biochem J       Date:  1992-05-15       Impact factor: 3.857

3.  Animal models of tuberculosis.

Authors:  U D Gupta; V M Katoch
Journal:  Tuberculosis (Edinb)       Date:  2005-10-24       Impact factor: 3.131

4.  Structure of human neutral endopeptidase (Neprilysin) complexed with phosphoramidon.

Authors:  C Oefner; A D'Arcy; M Hennig; F K Winkler; G E Dale
Journal:  J Mol Biol       Date:  2000-02-18       Impact factor: 5.469

5.  Kinetics of amyloid beta-protein degradation determined by novel fluorescence- and fluorescence polarization-based assays.

Authors:  Malcolm A Leissring; Alice Lu; Margaret M Condron; David B Teplow; Ross L Stein; Wesley Farris; Dennis J Selkoe
Journal:  J Biol Chem       Date:  2003-07-16       Impact factor: 5.157

6.  Structural basis for type II membrane protein binding by ERM proteins revealed by the radixin-neutral endopeptidase 24.11 (NEP) complex.

Authors:  Shin-ichi Terawaki; Ken Kitano; Toshio Hakoshima
Journal:  J Biol Chem       Date:  2007-04-24       Impact factor: 5.157

7.  Structural studies of a bifunctional inhibitor of neprilysin and DPP-IV.

Authors:  Christian Oefner; Sabine Pierau; Henk Schulz; Glenn E Dale
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2007-08-17

8.  Structural analysis of neprilysin with various specific and potent inhibitors.

Authors:  Christian Oefner; Bernard P Roques; Marie-Claude Fournie-Zaluski; Glenn E Dale
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2004-01-23

Review 9.  Scaling and assessment of data quality.

Authors:  Philip Evans
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2005-12-14

10.  Glycosylation site prediction using ensembles of Support Vector Machine classifiers.

Authors:  Cornelia Caragea; Jivko Sinapov; Adrian Silvescu; Drena Dobbs; Vasant Honavar
Journal:  BMC Bioinformatics       Date:  2007-11-09       Impact factor: 3.169

View more
  2 in total

1.  Structural analysis of Mycobacterium tuberculosis M13 metalloprotease Zmp1 open states.

Authors:  Wenguang G Liang; Jordan M Mancl; Minglei Zhao; Wei-Jen Tang
Journal:  Structure       Date:  2020-12-29       Impact factor: 5.006

2.  Molecular Basis for Omapatrilat and Sampatrilat Binding to Neprilysin-Implications for Dual Inhibitor Design with Angiotensin-Converting Enzyme.

Authors:  Urvashi Sharma; Gyles E Cozier; Edward D Sturrock; K Ravi Acharya
Journal:  J Med Chem       Date:  2020-05-08       Impact factor: 7.446

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.